[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"methamphetamine-disorders\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:methamphetamine-disorders":103},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,46,78],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100565073",false,"NCT06637436","PrEP Readiness Interventions for Sustained Motivation (PRISM)","Optimizing HIV Prevention for Highly Vulnerable Methamphetamine-using Sexual Minority Men","PRISM","Inclusion Criteria:\n\n* 18 years or older\n* Assigned male a birth\n* Self-reported methamphetamine use in the past 3 months\n* HIV-negative or unknown serostatus at baseline\n* Has not filled a PrEP prescription in the past 6 months\n\nExclusion Criteria:\n\n* Unwilling or unable to provide informed consent","ALL","18 Years",{"count":19,"type":20},400,"ESTIMATED","INTERVENTIONAL",[23],"NA","This is a hybrid type I randomized controlled trial to test the effectiveness of contingency management (CM) alone versus CM with motivational interviewing (MI) for optimizing entry or re-entry into the HIV prevention or care continua. A total of 400 participants will be randomized to CM (n = 200) or MI+CM (n = 200), all delivered via telehealth. Monthly follow-up assessments will be completed over 12 months to examine effectiveness MI+CM for the primary outcome - filling a pre-exposure prophylaxis (PrEP) or anti-retroviral therapy (ART) prescription (verified using a digital photo). Secondary outcomes will include: self-reported PrEP or ART clinical evaluation by a provider; self-reported meth and other substance use severity (ASSIST), and self-reported receptive and insertive condomless anal sex (CAS).",[26,27],"HIV","Methamphetamine Disorders",[29,30,31,32],"HIV prevention","Methamphetamine","Motivational Interviewing","Contingency Management","RECRUITING","2026-05-05",{"date":36,"type":37},"2026-05-07","ACTUAL",{"date":39,"type":37},"2025-01-28",{"date":41,"type":20},"2028-04-30",{"name":43,"class":44},"Florida International University","OTHER",1,{"id":47,"slug":4,"hasResults":10,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":52,"sex":16,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":58,"conditions":59,"keywords":60,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":45},"100628686","NCT07464873","Reliability, Validity, and Acceptability of a Novel Visual Scale for Estimating Daily Methamphetamine Use Among People Who Use Methamphetamine","PROJECT RESIN","Inclusion Criteria:\n\n* Age 20-40 inclusive\n* English speaking\n* Self-reports using methamphetamine at least once in the past 7 days (attempts will be made to enroll participants with varied frequencies of methamphetamine use)\n* At least 1cm of untreated occipital scalp hair\n* Hair is brown or black\n* Willing to provide a hair sample\n\nExclusion Criteria:\n\n* Participant, in the opinion of the investigators, would be unable to complete study procedures",true,"20 Years","40 Years",{"count":56,"type":20},100,"OBSERVATIONAL","PROJECT RESIN: This study is examining the reliability, validity, and acceptability of a novel visual scale for estimating daily methamphetamine use among people who use methamphetamine.",[27],[61,62,63,64,65,66],"methamphetamine","timeline","follow","back","timeline follow-back","resin","NOT_YET_RECRUITING","2026-03-09",{"date":70,"type":37},"2026-03-11",{"date":72,"type":20},"2026-03-15",{"date":74,"type":20},"2026-06-30",{"name":76,"class":77},"Phillip Coffin, MD, MIA","OTHER_GOV",{"id":79,"slug":4,"hasResults":10,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":84,"enrollmentInfo":85,"targetDuration":4,"studyType":21,"phases":87,"briefSummary":89,"conditions":90,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":45},"100571533","NCT06721494","A Single-Dose Study to Evaluate Safety and Efficacy of CS-1103 in Participants Receiving a Single Dose of Methamphetamine","A Phase 2 Single-Dose Study to Evaluate Safety and Efficacy of CS-1103 in Participants With Methamphetamine Use Disorder Not Seeking Treatment Receiving a Single Dose of Methamphetamine","Major Inclusion Criteria:\n\n1. Healthy participants aged 18 to 55 years, inclusive;\n2. Meets DSM-5 criteria for methamphetamine use disorder;\n3. Not seeking treatment for methamphetamine use disorder;\n4. Primary route of methamphetamine self-administration must be intravenous or smoking;\n5. Able to abstain from methamphetamine without experiencing severe withdrawal;\n6. A body mass index between 18 to 30 kg\u002Fm2, inclusive and a minimum body weight of 50 kg;\n7. Females must not be lactating and must have a negative pregnancy test during screening and admission.\n\nMajor Exclusion Criteria:\n\n1. Estimated glomerular filtration rate \\\u003C60 mL\u002Fmin\u002F1.73 m2;\n2. History of cardiovascular disease;\n3. Current moderate to severe use disorder for alcohol, cannabis, cocaine, opioids, or benzodiazepines;\n4. History of any clinically important disease or disorder which, in the opinion of the Investigator, may interfere with safe study participation.","55 Years",{"count":86,"type":20},40,[88],"PHASE2","The purpose of the study is to evaluate the safety, efficacy, and pharmacokinetics of four single, increasing doses of CS-1103, given by intravenous (IV) infusion in otherwise healthy, non-treatment seeking participants with methamphetamine use disorder in the presence of a clinically relevant dose of methamphetamine HCl (30 mg IV).",[91,27,92],"Methamphetamine Intoxication","Methamphetamine Abuse","2026-01-09",{"date":95,"type":37},"2026-01-12",{"date":97,"type":20},"2026-02-05",{"date":99,"type":20},"2026-09-11",{"name":101,"class":102},"Clear Scientific, Inc.","INDUSTRY",""]